Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
October 2, 2026 updated by: Janssen Research & Development, LLC
64407564MMY4002: PRE-APPROVAL ACCESS Single Patient Request (SPR) TREATMENT GUIDELINE for TALQUETAMAB for Treating Physician Use in Relapsed and Refractory Multiple Myeloma Concurrent With Relapsed and Refractory Light Chain (AL) Amyloidosis
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
August 12, 2022
First Submitted That Met QC Criteria
August 12, 2022
First Posted (Actual)
August 16, 2022
Study Record Updates
Last Update Posted (Actual)
October 6, 2026
Last Update Submitted That Met QC Criteria
October 2, 2026
Last Verified
October 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Neoplasms
- Disease Attributes
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Recurrence
- Multiple Myeloma
- talquetamab
Other Study ID Numbers
- CR109169
- 64407564MMY4002 (Other Identifier: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.